Gen-Probe's Q3 Revenues Inch Up 1 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Gen-Probe reported after the close of the market Thursday that its third-quarter revenues increased 1 percent as clinical diagnostic sales offset weakness in its blood screening business.

The San Diego-based molecular diagnostics firm brought in total revenues of $122.7 million for the three months ended Sept. 30, up from $121.2 million for the third quarter of 2008. Its clinical diagnostic sales for the quarter were $69.6 million, up from $55.5 million, while its blood screening sales dropped to $45.4 million from $52.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.